Is HCV Genotyping Cost-Effective Even When the Prevalences of Genotypes 2 and 3 are Low?

Yazar
Uraz, Suleyman
Tozun, Nurdan
Mert, Ali
Senturk, Hakan
Turkoglu, Salih
Tabak, Fehmi
Ozturk, Recep
Midilli, Kenan
Karaca, Cetin
Ozaras, Resat
Tahan, Veysel
EREN, FATİH
Danalioglu, Ahmet
Avsar, Erol
Üst veri
Tüm öğe kaydını göster
Özet
Background/Aims: The management of chronic hepatitis C virus (HCV) infection is costly. Genotyping determines the indication, probability of response.. and duration of treatment and the dose of ribavirin. Although genotyping is accepted cost-effective, the cost of genotyping in all of the patients to find out a minority may offset the gain.
Bağlantı
http://hdl.handle.net/20.500.12627/39480
Koleksiyonlar